Expanding the mutational spectrum of GCK in Turkish pediatric population

Vehap Topcu¹, Gonul Buyukyilmaz ², Keziban Toksoy Adiguzel², Mehmet Boyraz³ ¹Department of Medical Genetics, Ankara City Hospital, Ankara, Turkey ²Department of Pediatric Endocrinology, Ankara City Hospital, Ankara, Turkey ³Department of Pediatric Endocrinology, Ankara Yildirim Beyazit University Faculty of Medicine Ankara, Turkey

Correspondence

Vehap Topcu, Department of Medical Genetics, Ankara City Hospital, Ankara, Turkey

Email: avehaptopcu@gmail.com

Abstract

Heterozygous loss-of-function variants in *GCK* cause persistent, mildly elevated plasma glucose beginning at birth. Recently, clinical phenotype created by deleterious variants in *GCK* is called GCK-MODY, although currently registered as "MODY, type 2" (maturity-onset diabetes of the young type 2, MODY2, MIM # 125851) in OMIM. The hyperglycemia of GCK-MODY is a benign and non-progressive condition, usually suspected upon detection of hyperglycemia in adulthood. Medication is not essential, nevertheless, pregnant females may require special attention. Here, we report recurrent and novel *GCK* variants detected in 43 pediatric patients who were investigated for hyperglycemia by the referring pediatric endocrinologist. Electronic medical records (EMR) of the patients were collected and reviewed retrospectively. All patients applied to Ankara City Hospital between April 2019 and June 2022. *GCK* variants detected in *GCK* were checked with recent literature for a proper pathogenicity classification. In 43 patients, 28 distinct *GCK* variants were identified. Of these variants, 25 were classified as likely pathogenic/pathogenic variants (c.1342G>A, c.112C>T, c.1178T>C, c.130G>A, c.565A>G, c.208+3A>T, c.349G>C, c.863+5G>A, c.214G>A,

c.1292C>A, c.830_831deITG, c.106C>T, c.572G>A, c.107G>C, c.454T>C, c.793G>A, c.645C>A, c.377T>A, c.667G>A, c.46-1G>A, c.149A>C, c.1079C>G, c.401T>C, c.758T>G, c.467_483+6del; NM_000162.5), while remaining 3 variants (c.950A>C, c.186G>T, c.188G>A; NM_000162.5) were classified as variant of uncertain significance. According to the variant effect, missense variants accounted for the majority (71%; 20/28), followed by splice junction (14%; 4/28), premature termination (7%; 2/28), frameshift (4%; 1/28), and synonymous (4%; 1/28) alterations. There were 3 novel variants: c.830_831del, c.377T>A, c.467_483+6del.

KEYWORDS

glucokinase, hyperglycemia, GCK-MODY, monogenic diabetes, pediatric patients

INTRODUCTION

First evidence of monogenic diabetes emerged from the study that suggested a role of glucokinase locus in French MODY families (Froguel et al., 1992; Froguel et al., 1993). Clinical phenotype caused by heterozygous inactivating variants in glucokinase (GCK) enzyme is recently named GCK-MODY, also known as MODY2 (OMIM entry #125851). Frequency of pathogenic variants in glucokinase varies in different geographical regions and comprises of 30% to 60% of all MODY phenotypes (Shields et al., 2010). Turkish MODY series figured a similar frequency, ranging between %24-%60 (Aydogan et al., 2022). Albeit a prevalence of 1 in 1000 individuals is proposed (Chakera et al., 2015), a certain proportion of the GCK-MODY is hidden likely because of misdiagnosis or coincidence with type 1 or type 2 diabetes (Martin et al., 2008). It's prevalence among all diabetes patients is around 2-5% worldwide.

GCK is copiously expressed in the pancreas, hepatocytes, and brain tissues. It tunes insulin secretion in response to alterations in blood glucose levels, thus keeping serum glucose levels over a physiological range. The cellular expression of GCK isoforms is controlled by different enzymes, regulators, and cellular substances. While the islet-specific isoform is regulated directly by glucose, the liver-specific isoform is under the control of both insulin and

glucokinase regulatory protein (GKRP) (Choi, Seo, Kyeong, Kim, & Kim, 2013; Matschinsky, 1990). Monoallelic loss of function variants is sufficient to exhibit disease features. Over 1000 hundred mutations are registered in the Human Gene Mutation Database (<u>https://portal.biobase-international.com/hgmd/pro/start.php</u>), scattering evenly along the exons and exon-intron boundaries.

A mild fasting hyperglycemia presenting right after birth is the hallmark of GCK-MODY (Prisco, lafusco, Franzese, Sulli, & Barbetti, 2000); however, in older ages it is underdiagnosed because of the lack of classical symptoms and diabetic complications (Steele et al., 2014). Frequently, GCK-MODY is uncovered in a routine medical investigation. A fasting plasma glucose (FPG) between 5.4 and 8.3 mmol/L and glycated hemoglobin A1c (HbA1c) between 5.8 and 7.6% (40–60 mmol/mol) are in favor of GCK-MODY diagnosis (Chakera et al., 2015). Oral glucose tolerance test reveals a trivial incremental elevation of the blood glucose and a mild increase in A1c (HbA1c) (Steele et al., 2013). Accurate diagnosis is crucial to differentiate GCK-MODY from early type 1 and type 2 diabetes for a convenient counseling and to pick appropriate course of management and surveillance of the patients and family members with GCK-MODY. Today, clinical diagnosis is confirmed conveniently using widely available molecular genetic testing, mostly in adults (Chakera et al., 2015; Vionnet et al., 1992). Molecular genetic testing in GCK-MODY yields a high diagnostic rate, particularly in pedigrees with a dominant inheritance. Persistent fasting hyperglycemia remains stable throughout life, irrespective of mutation type. So, treatment is scarcely recommended as microvascular and macrovascular complications are not expected in GCK-MODY; however, pregnancy is an exception for which insulin treatment is indicated if the fetus has macrosomia in second-trimester fetal ultrasound (American Diabetes, 2020). Thus, detection of macrosomia may be an indicator of a fetus without an inherited pathogenic GCK variant.

Here, we report 28 distinct *GCK* variants observed in a series of 43 patients in Ankara City Hospital, Medical Genetics Laboratory referred by Clinic of Pediatric Endocrinology. We have

identified published and novel variants in *GCK*, some of which have not been reported in Turkish GCK-MODY patients.

MATERIALS AND METHODS

Patients

In this retrospective study, we screened our in-house database to find individuals with a reported *GCK* variant. We included only patients referred from pediatric endocrinology outpatient clinic of Ankara City Hospital (Ankara, Türkiye) between 2019 April – 2022 June, totally 43 patients (27 female, 16 male) aged 0-18 years old. All patients had a clinical profile consistent with GCK-MODY. The following clinical and laboratory variables were collected using EMR: gender, age, reason for consultation, body mass index (BMI), and laboratory investigations including glycosylated hemoglobin A1c, FPG, 2-hour plasma glucose (2h-PG), fasting insulin (Fins) concentration, and 2-hour insulin concentration (2h-Ins). All patients were negative for anti-glutamic acid decarboxylase, anti-islet cell, and anti-insulin antibodies, thus type 1 diabetes were ruled out.

Genetic analysis and variant classification

Genomic DNA was isolated from peripheral blood using QIAamp DNA mini kit (Qiagen, Hilden, Germany). We screened all exons and ± 20 bp exon-intron boundaries of *GCK* using Next Generation Sequencing (NGS). Sequencing libraries were prepared with CDHS-14622Z-506 QIAseq Targeted DNA Custom Panel (Qiagen, Hilden, Germany) and sequenced on Illumina NovaSeq 6000 platform (Illumina, San Diego, CA, USA). Read mapping and variant calling were performed using CLC Genomics Workbench (CLC-GWB, Qiagen). Variant analysis was performed on QIAGEN Clinical Insight (QCI) interpret software (QIAGEN, Hilden, Germany). Integrative Genome Viewer (IGV) was used for the visual analysis of depth coverage, sequences quality and variants identification. Next generation sequencing (NGS) covered 100% of the bases with more than 30x coverage. *GCK* variants were reported with reference to the canonical transcript NM_000162.5 (β-cell isoform). Variants were classified according to the ACMG/AMP international guidelines for interpreting sequence variants (Richards et al., 2015), a system that helps assign a variant one of five classification categories: Pathogenic (P) ;likely pathogenic (LP), variant of uncertain significance (VUS), likely benign (LB), or benign (B). In the present study, we solely reported variants classified as pathogenic/likely pathogenic or uncertain significance. We searched all variants in dbSNP, ClinVar, HGMD, and medical literature; a *GCK* variant was deemed de novo if it was not registered in one of these variants databases or in published literature.

Statistical analysis

All statistical analyses were carried out with the Statistical Package for Social Sciences (SPSS 15.0 for Windows, Chicago, IL, USA).

Ethics approval

A written informed consent of patients and/or his/her parents is obtained prior to routine genetic testing. Retrospective analysis of the patient data was approved by the ethics committee of Ankara City Hospital (E2-22-2102). This research was conducted in accordance with 2013 Declaration of Helsinki.

RESULTS

Clinical and Biochemical Characteristics

Clinical data of the patients are summarized in (**Table 1, Supplementary Figure 1**). GCK-MODY does not show considerable clinical variability. The biochemical characteristics of our patients were comparable to those reported previously.

The mean age of the patients was 9.3 years old. The gender distribution was 27 females (63%) and 16 males (37%) (**Figure 1**). The main reason for the consultation with medical genetics to get *GCK* sequenced was the laboratory investigation of persistent fasting hyperglycemia in all but two patients, who had polydipsia, polyuria, and polyphagia as

primary complaints. Anthropometric measurement was available in 32 patients; the proportion of the patients for those with normal weight (84,4%), below-normal weight (6,3%), obesity (6,3%), and overweight (3,1%) was determined according to BMI.

All patients had a glycosylated hemoglobin A1c<%8 and were found negative for type 1 diabetes-related autoantibodies against glutamic acid decarboxylase (GAD), islet cells, and insulin. Medical history revealed coeliac disease in one patient (GCK-11), and Hashimoto's disease (GCK-22) in another. None of the patients had hypertension, acanthosis nigricans (data was available in 33 of 43), microvascular complications, or diabetic ketoacidosis (DKA). There was not any patient on medication.

GCK Variants

We observed 28 distinct variants in 43 patients, of these, 17 were classified as pathogenic (P), 8 were classified as likely pathogenic (LP), and 3 were classified as uncertain significance (VUS) according to the ACMG classification system (Richards et al., 2015). According to the effect on the transcript, there were 20 missense (71,4%) variants, followed by 4 splice site/near-splice-site (14,3%), 2 premature termination (7,1%), 1 frameshift (3,6%), and 1 synonymous (3,6%) alterations (**Table 2**). So, the majority of the GCK variants were detected in the coding sequence and uniformly distributed along the protein (**Figure 2**). We checked all variants from dbSNP, ClinVar, and HGMD databases, as well as searched medical literature (PubMed and Google Scholar). We regarded a variant as novel if it was not recorded in any of the databases or medical literature. We have observed 3 novel variants (c.830_831delTG, c.377T>A, c.467_483+6del), while the remaining 25 variants in this series were reported elsewhere. Four variants (c.1178T>C, c.208+3A>T, c.112C>T, c.1079C>G) were observed in more than one patient in this series (**Supplementary Table 1**).

DISCUSSION

We present the mutational spectrum of 43 pediatric patients referred for *GCK* sequencing to confirm the clinical diagnosis of GCK-MODY, the most prevalent form of monogenic

diabetes. Thus, genetic analysis revealed 28 distinct rare *GCK* variants in our patient series, each patient having a single *GCK* alteration in one allele. Main complaint of the patients was fasting hyperglycemia and mild increase in the 2h-PG level revealed in routine or incidental blood glucose testing, while lacking classic signs of type 2 diabetes. Although GCK-MODY has an insidious onset, it has a high diagnosis rate before age 25; in agreement, ~55% of our patients were diagnosed molecularly in the first decade. Awareness of this entity among pediatric endocrinologists and accessibility to DNA tests fostered prompt molecular diagnosis in younger ages.

Several Turkish patient series of GCK-MODY have been published previously, which figure out an approximate landscape of the GCK variants in the Turkish population (Agladioglu et al., 2016; Altan et al., 2020; Anik et al., 2015; Ates et al., 2021; Aykut et al., 2018; Bolu, Eroz, Dogan, Arslanoglu, & Dundar, 2020; Dundar, 2023; Duzkale & Emiroglu, 2023; Haliloglu et al., 2016; İşleyen & Semih, 2019; Ozdemir et al., 2018; Sağsak, Önder, Kendirci, Yıldız, & Doğan, 2022; Siklar & Berberoglu, 2016; Yalcintepe et al., 2021; Yilmaz Uzman et al., 2022). Still, only 58% of the variants detected in our patients overlapped with those in the previous series of the Turkish population. Therefore, 42% (12/28) of the variants we observed in our patients were reported for the first time in Turkish patients (**Supplementary Table 1**). In this regard, our report would further reflect the geographical view of *GCK* variants.

GCK encodes for 465 amino acid-length Hexokinase that consists of two subdomains, namely, hexokinase small subdomain (HSS, 67-203) and hexokinase large subdomain (HLS, 204-443). Over 1000 variants are registered in the Human Gene Mutation Database (Adzhubei et al., 2010), and there is no hot spot region or group of mutations to screen as a first-tier step for GCK-MODY *(Osbak et al., 2009)*. In conformity, mutations detected in our patients tended to distribute along the exons and exon-intron junctions of the GCK uniformly; nevertheless, they were slightly more populated relatively in HSS compared to HLS concerning the domain size (Figure. Distribution of the variants on GCK). It was noteworthy that variants c.1178T>C (9 patients), c.208+3A>T (6 patients), c.112C>T (2 patients),

c.1079C>G (2 patients) were observed in more than two cases, which, we think, is a chance occurred in our patient group, or these mutations may be more common in general. Regarding variant effect, most (71.4%) were missense type, while the remaining (28.6%) were causing premature termination, frameshift, synonymous events, or splice region alterations with possible harmful effects on proper splicing. Of these variants, 3 were novel.

Variant classification guidelines mention scrutinizing for experimental data of any variant in literature, which helps a more thorough and confident classification. The functional consequence of sequence variants on glucokinase activity is evaluated through protein stability and enzyme kinetic assays. Our comprehensive literature search yielded research papers including functional evidence for 11 of 28 variants detected in our patients, which prompted us to assign the PS3 criterion of the ACMG system (Supplementary Table 1). Functional evaluation of c.863+5G>A splice variant (GCK 14) was carried out using a minigene assay, which showed the deletion of exon 7 (Bouvet et al., 2023). In addition, regarding H50P alteration (GCK_45), there was no first-hand functional data; however, a nonsynonymous alteration at the same position (H50D) was experimented with by Raimondo et al. (2014), which demonstrated altered protein stability and kinetics. Thus, we deduced that H to P alteration would be damaging to the enzyme function given that Proline (P) does not have an electrically charged side chain and is smaller in size compared to Histidine (H), namely two amino acids have different molecular properties. Likewise, we did not find any direct functional evidence for R191Q but saw R191W was experimented with by Wang et al. (2019). Consequently, both H50D and R191Q were given PM5 instead of PS3, nevertheless, either variant ensured adequate points to be classified as pathogenic. Other variants with a functional study were Arg36Trp (Osbak et al., 2009), Gly44Ser (Wang et al., 2019), Gly72Arg (Raimondo et al., 2014), Gly223Ser (Valentinova et al., 2012), Glu265Lys (Osbak et al., 2009), Met393Thr (Raimondo et al., 2014), Thr431Lys (Lin et al., 2019), and Gly448Ser (Li et al., 2022).

In GCK_26, we observed a rare synonymous variant (c.189G>T, Val63Val), annotated as a disease-causing variant according to the Human Gene Mutation Database (HGMD). c.189G>T is a rare variant (f = 0.00000398 in the gnomAD Exomes); however, splice predicting algorithms predicted no impact on the splice consensus sequence nor the creation of a new splice site (**Supplementary Figure 2**). Thus, we preferred to classify it as a likely benign/uncertain significance based on PM2 and BP4/BP7 criteria of the ACMG classification (Richards et al., 2015). To the best of our knowledge, there is no functional study assessing the splice effect of this variant.

Conclusion

As Sanger sequencing and NGS became widespread and readily available for most healthcare facilities at a low cost, more healthcare practitioners now pick direct genetic testing based on suspicion of GCK-MODY, refraining from unnecessary laboratory investigation. The lack of hotspot variant(s)/region in *GCK* makes it credible to sequence all coding exons. One may prefer to analyze merely *GCK* or in a panel made up of prevalent monogenic diabetes genes (HNF4A, HNF1A, HNF1B, etc.). Given that GCK-MODY is straightforwardly distinguished from other monogenic forms, the NGS gene panel approach is not a requisite (Carroll & Murphy, 2013). In GCK-MODY, the patient and his/her family are informed that GKC heterozygotes do not require medication nor a surveillance program, whereas homozygous individuals present a severe outcome, known as Permanent neonatal diabetes mellitus-1 (MIM # 606176), which demands insulin treatment soon after birth. We consider it wise to communicate this piece of information to the parents and relatives, particularly when families are from geographical regions where endogamy is common.

Our study has some limitations. Retrospective data is obtained from a small group of pediatric patients with pathogenic GCK variants, so is not a broad representation of all possible *GKC* variants in the Turkish population.

The lack of segregation study of a *GCK* variant in a family was unfavorable in terms of exploiting ACMG criteria such as PP1 (co-segregation in affected family members) and PS2 (de novo variant). Nevertheless, the majority of the variants observed in this study fulfilled sufficient evidence to be LP/P even in the absence of PP1 and PS2. Variants H317P, V62V, and R63H remained uncertain significance as of now since we could not employ corresponding ACMG criteria relating to family study.

In most of our patients, information regarding the family history of individuals with diabetes was missing, so we did not have respectable family history data to provide. We are aware that a family history of diabetes at a young age (usually before 30 years of age) and a pedigree suggestive of monogenic diabetes are useful criteria along with biochemical evaluations in selecting patients before genetic testing. In our study, pediatric endocrinologists opted for *GCK* sequencing mainly resting on biochemical evidence.

Declaration of interest

The authors declare no conflicts of interest.

Funding statement

This research received no specific grant from any funding agency in the public, commercial,

or not-for-profit sectors.

Author contribution statement

V.T.: genetic analysis, interpreting data, writing—original draft preparation; G.B & K.T.A.: data curation, review and editing; M.B.; supervision, review and editing. All authors have read and agreed to the current version of the manuscript.

Data availability statement

The patient data generated during and/or analyzed during the current study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

- Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. *Nat Methods*, 7(4), 248-249. doi:10.1038/nmeth0410-248
- Agladioglu, S. Y., Aycan, Z., Cetinkaya, S., Bas, V. N., Onder, A., Peltek Kendirci, H. N., . . . Ceylaner, S. (2016). Maturity onset diabetes of youth (MODY) in Turkish children: sequence analysis of 11 causative genes by next generation sequencing. *J Pediatr Endocrinol Metab*, *29*(4), 487-496. doi:10.1515/jpem-2015-0039
- Altan, M., Anık, A., Işık Bayar, N. T., Bozkurt, G., Ünüvar, T., & Anık, A. (2020). Clinical, Laboratory and Genetic Characteristics of Children with GCK-MODY (MODY2): Report of Four Novel Variants in GCK Gene. *TP*, *1*(1), 5-10. doi:10.5222/tp.2020.58076

American Diabetes, A. (2020). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care, 43*(Suppl 1), S14-S31. doi:10.2337/dc20-S002

- Anik, A., Catli, G., Abaci, A., Sari, E., Yesilkaya, E., Korkmaz, H. A., . . . Bober, E. (2015). Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing. *J Pediatr Endocrinol Metab*, 28(11-12), 1265-1271. doi:10.1515/jpem-2014-0430
- Ates, E. A., Ustay, O., Polat, H., Apaydin, T., Elbasan, O., Yildirim, O., & Guney, A. I. (2021). Genetic and Clinical Characterization of Patients with Maturity-Onset of Diabetes of the Young (MODY): Identification of Novel Variations. *Balkan Med J, 38*(5), 272-277. doi:10.5152/balkanmedj.2021.20155
- Aydogan, H. Y., Gul, N., Demirci, D. K., Mutlu, U., Gulfidan, G., Arga, K. Y., . . . Satman, I. (2022). Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients. *OMICS*, 26(4), 218-235. doi:10.1089/omi.2022.0006
- Aykut, A., Karaca, E., Onay, H., Goksen, D., Cetinkalp, S., Eren, E., ... Ozkinay, F. (2018). Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations. *Gene, 641*, 186-189. doi:10.1016/j.gene.2017.10.057
- Bolu, S., Eroz, R., Dogan, M., Arslanoglu, I., & Dundar, I. (2020). Genotype-Phenotype Characteristics of Turkish Children With Glucokinase Mutations Associated Maturity-Onset Diabetes of the Young. *Indian Pediatr, 57*(11), 1037-1039. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32533685
- Bouvet, D., Blondel, A., de Sainte Agathe, J.-M., Leroy, G., Saint-Martin, C., & Bellanné-Chantelot, C. (2023). Evaluation in Monogenic Diabetes of the Impact of GCK, HNF1A, and HNF4A Variants on Splicing through the Combined Use of In Silico Tools and Minigene Assays. Human Mutation, 2023, 6661013. doi:10.1155/2023/6661013
- Carroll, R. W., & Murphy, R. (2013). Monogenic diabetes: a diagnostic algorithm for clinicians. *Genes (Basel), 4*(4), 522-535. doi:10.3390/genes4040522
- Chakera, A. J., Steele, A. M., Gloyn, A. L., Shepherd, M. H., Shields, B., Ellard, S., & Hattersley, A. T. (2015). Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. *Diabetes Care*, *38*(7), 1383-1392. doi:10.2337/dc14-2769
- Choi, J. M., Seo, M. H., Kyeong, H. H., Kim, E., & Kim, H. S. (2013). Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. *Proc Natl Acad Sci U S A*, *110*(25), 10171-10176. doi:10.1073/pnas.1300457110
- Dundar, I. (2023). Incidental cause of mild hyperglycemia in children: Genetic, clinical, and follow-up features of glucokinase-MODY diabetes. *Annals of Medical Research, 30*(2), 238-242. Retrieved from https://www.annalsmedres.org/index.php/aomr/article/view/4367

Duzkale, N., & Emiroglu, C. (2023). Investigation of the Mutation Spectrum in Pediatric Patients with Maturity-Onset Diabetes of Youth (MODY): Experience from a Diagnostic Center in Türkiye. *Clinical Diabetology*, *12*(4), 232-238. doi:{}

- Froguel, P., Vaxillaire, M., Sun, F., Velho, G., Zouali, H., Butel, M. O., . . . et al. (1992). Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. *Nature*, 356(6365), 162-164. doi:10.1038/356162a0
- Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., . . . et al. (1993). Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. *N Engl J Med, 328*(10), 697-702. doi:10.1056/NEJM199303113281005
- Haliloglu, B., Hysenaj, G., Atay, Z., Guran, T., Abali, S., Turan, S., . . . Ellard, S. (2016). GCK gene mutations are a common cause of childhood-onset MODY (maturity-onset diabetes of the young) in Turkey. *Clin Endocrinol (Oxf), 85*(3), 393-399. doi:10.1111/cen.13121
- İşleyen, F., & Semih, B. (2019). Adıyaman İlindeki Diyabetik Çocukların Epidemiyolojik Özellikleri. *Güncel Pediatri, 17*(1), 1-16.
- Li, Z., Li, K., Sun, Y., Jiang, X., Liu, J., Li, J., . . . Xu, C. (2022). Mutations in GCK May Lead to MODY2 by Reducing Glycogen Synthesis. *Adv Biol (Weinh), 6*(11), e2200097. doi:10.1002/adbi.202200097
- Lin, D. C., Huang, C. Y., Ting, W. H., Lo, F. S., Lin, C. L., Yang, H. W., . . . Lee, Y. J. (2019). Mutations in glucokinase and other genes detected in neonatal and type 1B diabetes patient using whole exome sequencing may lead to disease-causing changes in protein activity. *Biochim Biophys Acta Mol Basis Dis, 1865*(2), 428-433. doi:10.1016/j.bbadis.2018.11.013
- Martin, D., Bellanne-Chantelot, C., Deschamps, I., Froguel, P., Robert, J. J., & Velho, G. (2008). Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). *Diabetes Care, 31*(7), 1321-1323. doi:10.2337/dc07-2017
- Matschinsky, F. M. (1990). Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. *Diabetes, 39*(6), 647-652. doi:10.2337/diab.39.6.647
- Osbak, K. K., Colclough, K., Saint-Martin, C., Beer, N. L., Bellanne-Chantelot, C., Ellard, S., & Gloyn, A. L. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. *Hum Mutat, 30*(11), 1512-1526. doi:10.1002/humu.21110
- Ozdemir, T. R., Kirbiyik, O., Dundar, B. N., Abaci, A., Kaya, O. O., Catli, G., . . . Erdogan, K. M. (2018). Targeted next generation sequencing in patients with maturity-onset diabetes of the young (MODY). *J Pediatr Endocrinol Metab, 31*(12), 1295-1304. doi:10.1515/jpem-2018-0184
- Prisco, F., lafusco, D., Franzese, A., Sulli, N., & Barbetti, F. (2000). MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of "neonatal diabetes"? *Diabetologia, 43*(10), 1331-1332. doi:10.1007/s001250051531
- Raimondo, A., Chakera, A. J., Thomsen, S. K., Colclough, K., Barrett, A., De Franco, E., . . . International, N. D. M. C. (2014). Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. *Hum Mol Genet*, 23(24), 6432-6440. doi:10.1093/hmg/ddu360
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., . . . Committee, A. L. Q.
 A. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*, *17*(5), 405-424. doi:10.1038/gim.2015.30
- Sağsak, E., Önder, A., Kendirci, H. N. P., Yıldız, M., & Doğan, Ö. A. (2022). Evaluation and Long-term Monitoring of Patients with MODY, and Description of Novel Mutations. *JAREM. Journal of Academic Research in Medicine*, *12*(2), 99.

- Shields, B. M., Hicks, S., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Ellard, S. (2010). Maturity-onset diabetes of the young (MODY): how many cases are we missing? *Diabetologia*, 53(12), 2504-2508. doi:10.1007/s00125-010-1799-4
- Siklar, Z., & Berberoglu, M. (2016). Current Status of Childhood Hyperinsulinemic Hypoglycemia in Turkey. *J Clin Res Pediatr Endocrinol, 8*(4), 375-380. doi:10.4274/jcrpe.2991
- Steele, A. M., Shields, B. M., Wensley, K. J., Colclough, K., Ellard, S., & Hattersley, A. T. (2014). Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. *JAMA*, 311(3), 279-286. doi:10.1001/jama.2013.283980
- Steele, A. M., Wensley, K. J., Ellard, S., Murphy, R., Shepherd, M., Colclough, K., ... Shields, B. M. (2013). Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. *PLoS One, 8*(6), e65326. doi:10.1371/journal.pone.0065326
- Valentinova, L., Beer, N. L., Stanik, J., Tribble, N. D., van de Bunt, M., Huckova, M., . . . Gloyn, A. L. (2012). Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia. *PLoS One, 7*(4), e34541. doi:10.1371/journal.pone.0034541
- Vionnet, N., Stoffel, M., Takeda, J., Yasuda, K., Bell, G. I., Zouali, H., . . . et al. (1992). Nonsense mutation in the glucokinase gene causes early-onset non-insulindependent diabetes mellitus. *Nature, 356*(6371), 721-722. doi:10.1038/356721a0
- Wang, Z., Diao, C., Liu, Y., Li, M., Zheng, J., Zhang, Q., . . . Xiao, X. (2019). Identification and functional analysis of GCK gene mutations in 12 Chinese families with hyperglycemia. *J Diabetes Investig*, 10(4), 963-971. doi:10.1111/jdi.13001
- Yalcintepe, S., Ozguc Comlek, F., Gurkan, H., Demir, S., Atli, E. I., Atli, É., . . . Tutunculer Kokenli, F. (2021). The Application of Next Generation Sequencing Maturity Onset Diabetes of the Young Gene Panel in Turkish Patients from Trakya Region. J Clin Res Pediatr Endocrinol, 13(3), 320-331. doi:10.4274/jcrpe.galenos.2021.2020.0285
- Yilmaz Uzman, C., Erbas, I. M., Giray Bozkaya, O., Paketci, A., Caglayan, A. O., Abaci, A., . . Demir, K. (2022). Hemoglobin A(1C) can differentiate subjects with GCK mutations among patients suspected to have MODY. *J Pediatr Endocrinol Metab, 35*(12), 1528-1536. doi:10.1515/jpem-2022-0381

No. of patients Mean ± SD 43 116,3 15,9 FPG (mg/dL) 2h-PG (mg/dL) 32 148,1 37,5 HbA1c (%) 43 6,4 0,5 Fins (mU/L) 42 7,9 7,7 2h-Ins (mU/L) 30 35,1 39,8 C-peptide (µg/L) 41 1,0 0,6

Table 1 General characteristics of the patients


Data is expressed as mean ± SD. FPG: Fasting plasma glucose; 2h-PG: 2-hour plasma glucose; Fins: Fasting insulin; 2h-Ins: 2-hour insulin.

Case ID	Gender	Nucleotide change	Protein effect	Variant effect	Zygosity	Classification	ACMG criteria
GCK_1	male	c.1342G>A	Gly448Ser	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
GCK_2	female	c.112C>T	Gln38*	Premature termination	Het	Р	PVS1, PM2, PP5
GCK_3	male	c.950A>C	His317Pro	Missense	Het	VUS	PM1, PM2, PM5, BP4
GCK_4	female	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
GCK_5	female	c.758T>G	Val253Gly	Missense	Het	Р	PM1, PM2, PM5, PP3, PP5
iCK_7	female	c.130G>A	Gly44Ser	Missense	Het	Р	PS3, PM1, PM2, PM5, PP3, PP5
СК_8	female	c.565A>G	lle189Val	Missense	Het	LP	PM1, PM2, PM5, PP5
СК_9	female	c.467_483+6de	n/a	Splice site	Het	Р	PVS1, PM2
CK_10	female	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
CK_11	female	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5
CK_12	male	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
CK_13	female	c.349G>C	Gly117Arg	Missense	Het	LP	PM1, PM2, PP3
CK_14	male	c.863+5G>A	n/a	Near-splice-site	Het	LP	PS3, PM2, PP3, PP5
CK_16	female	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
CK_17	male	c.214G>A	Gly72Arg	Missense	Het	Р	PS1, PS3, PM1, PM2, PP3, PP5
CK_18	male	c.1292C>A	Thr431Lys	Missense	Het	LP	PS3, PM1, PM2, PP3
_ СК_19	female	c.830_831de	Va 277fs*13	Frameshift	Het	Р	PVS1, PM2
_ СК_20	female	 c.112C>T	G n38*	Premature termination	Het	Р	PVS1, PM2, PP5
_ СК_21	female	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5
_ СК_22	female	c.106C>T	Arg36Trp	Missense	Het	Р	PS3, PM1, PM2, PM5, PP3, PP
 СК_23	female	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5
CK_24	male	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5
 СК_26	female	c.572G>A	Arg191GIn	Missense	Het	Р	PM1, PM2, PM5, PP3, PP5
CK_27	male	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
CK_28	female	c.186G>T	Val62Val	Synonymous	Het	VUS	PM2, PP5, BP7
 СК_29	female	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
_ СК_30	female	c.107G>C	Arg36Pro	Missense	Het	Р	PM1, PM2, PM5, PP3, PP5
CK_32	male	c.454T>C	Phe152Leu	Missense	Het	P	PS1, PM1, PM2, PM5, PP3, PP
CK_33	male	c.188G>A	Arg63His	Missense	Het	VUS	PM1, PM2
CK_34	male	c.1178T>C	Met393Thr	Missense	Het	P	PS3, PM1, PM2, PP3, PP5
CK_35	female	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5
CK_36	female	c.208+3A>T	n/a	Near-splice-site	Het	LP	PM2, PP3, PP5

GCK_38	female	c.793G>A	Glu265Lys	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
GCK_39	female	c.645C>A	Tyr215*	Premature termination	Het	Р	PVS1, PM2, PP5
GCK_40	male	c.1079C>G	Ser360Trp	Missense	Het	LP	PM1, PM2, PP3, PP5
GCK_42	male	c.377T>A	lle126Asn	Missense	Het	LP	PM1, PM2, PP3
GCK_43	female	c.667G>A	Gly223Ser	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
GCK_44	female	c.46-1G>A	n/a	Splice site	Het	Р	PVS1, PM2, PP5
GCK_45	female	c.149A>C	His50Pro	Missense	Het	Р	PS3, PM1, PM2, PM5, PP3, PP5
GCK_46	female	c.1079C>G	Ser360Trp	Missense	Het	LP	PM1, PM2, PP3, PP5
GCK_47	male	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5
GCK_48	male	c.401T>C	Leu134Pro	Missense	Het	LP	PM1, PM2, PP3, PP5
GCK_49	male	c.1178T>C	Met393Thr	Missense	Het	Р	PS3, PM1, PM2, PP3, PP5

GCK variants are indicated as nucleotide changes with respect to GenBank cDNA sequence (NM_000162.5), and protein effects (NP_000153.1) according to Human Genome Variation Society (HGVS) guidelines. The effects of variants were interpreted according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. n/a, not applicable; P, pathogenic, LP, likely pathogenic, VUS, variant of uncertain significance; het, heterozygous.

Figure 1





Gender and age distribution of the patients. A) Bar graph for gender distribution and B) Whisker plot for age distribution.

Figure 2




Figure 2

Distribution of the variants on Glucokinase. HSS, hexokinase small subdomain; HLS, hexokinase large subdomain. Variants are colorcoded: pathogenic, red; likely pathogenic, light red; variant of uncertain significance, gray.